Abstract
Chronic lymphocytic leukemia (CLL) is associated with physical dysfunction and low overall fitness that predicts poor survival following commencement of treatment. However, it remains unknown whether higher fitness in CLL patients provides anti-oncogenic effects. We identified ten fit (CLL-FIT) and ten less fit (CLL-UNFIT) treatment-naïve CLL patients from 144 CLL patients who completed a set of physical fitness and performance tests. Patient plasma was used to determine its effects on in vitro 5-day growth/viability of three B-cell cell lines (OSU-CLL, Daudi and Farage). Plasma exosomal miRNA profiles, circulating lipids, lipoproteins, inflammation levels, and immune cell phenotypes were also assessed. CLL-FIT was associated with fewer viable OSU-CLL cells at Day 1 (p=0.003), Day 4 (p=0.001) and Day 5 (p=0.009). No differences between groups were observed for Daudi and Farage cells. Of 455 distinct exosomal miRNAs identified, 32 miRNAs were significantly different between groups. Of these, 14 miRNAs had ≤-1 or ≥1 log2 fold differences. CLL-FIT patients had 5 exosomal miRNAs with lower expression and 9 miRNAs with higher expression. CLL-FIT patients had higher HDL cholesterol, lower inflammation, and lower levels of triglyceride components (all p<0.05). CLL-FIT patients had lower frequencies of low-differentiated NKG2+/CD158a/bneg (p=0.015 and p=0.014) and higher frequencies of NKG2Aneg/CD158b+ mature NK-cells (p=0.047). Absolute numbers of lymphocytes including CD19+/CD5+ CLL-cells were similar between groups (p=0.359). Higher physical fitness in CLL patients is associated with altered CLL-like cell line growth in vitro, and with altered circulating and cellular factors indicative of better immune functions and tumor control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Duke Claude D. Pepper Older Americans Independence Center Pilot Study Award (National Institutes of Health, National Institute on Aging P30-AG028716), National Institutes of Health, National Heart, Lung, and Blood Institute T32 grant (T32HL007057), the Durham Veterans Affairs Medical Center Research Service, an American Society of Hematology Scholars Award, and the Duke University Center for AIDS Research NIH funded program (P30 AI 64518).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Duke University Medical Center Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during the present study are not publicly available, owing to the risk of disclosure or deduction of private individual information, but they are available from the corresponding author on reasonable request.
Abbreviations
- 6MWT
- 6-minute walk test
- BCAA
- branch chain amino acid
- CBC
- complete blood count
- CD
- cluster of differentiation
- CLL
- Chronic Lymphocytic Leukemia
- CLL-IPI
- Chronic Lymphocytic Leukemia – International Prognostic Index
- DMSO
- Dimethyl sulfoxide
- DPBS
- Dulbecco’s phosphate buffered saline
- EBV
- Epstein Barr Virus
- EDTA
- Ethylenediaminetetraacetic acid
- eVO2peak
- estimated peak volume of oxygen consumption
- FBS
- fetal bovine serum
- FFA
- Free Fatty Acids
- FMO
- flow minus one
- HDL
- high-density lipoprotein
- ICAM-1
- Intercellular Adhesion Molecule 1
- IFN
- interferon
- IGHV
- immunoglobulin heavy chain variable region genes
- IL
- interleukin
- IPAQ
- Incidental and Planned Activity Questionnaire
- KIR
- Killer immunoglobulin-like receptor
- LDL
- low-density lipoprotein
- LP-IR
- Lipoprotein Insulin Resistance Index
- miRNA
- micro-RNA
- NK-cell
- Natural Killer Cell
- NKG2
- CD94/NK group 2 member
- NMR
- nuclear magnetic resonance
- OSU-CLL
- Ohio State University-Chronic Lymphocytic Leukemia
- PBMC
- peripheral blood mononuclear cell
- PI
- propidium iodide
- RNA
- ribonucleic acid
- RPMI
- Roswell Park Memorial Institute
- SBAS
- Stanford Brief Activity Survey
- SPPB
- short physical performance battery
- STAT
- Signal transducer and activator of transcription
- TGFβ
- Transforming growth factor β
- TNFα
- tumor necrosis factor α
- TRL
- triglyceride rich lipoprotein
- TRLP
- triglyceride rich lipoprotein particle
- TUG
- timed-up and go
- UMI
- Unique Molecular Indices